{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":1320,"summary":"Hosted by Corey with the Story. Stay informed with the latest business, stock market, and finance headlines, updates, and breaking stories delivered daily in quick, engaging episodes. Subscribe! The Daily News Now! — Every city. Every story. AI-powered. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-06-17T18:18:57.837082+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"Vertex Pharma Smashes Earnings, Highlights New Drugs","slug":"vertex-pharma-smashes-earnings-highlights-new-drugs","published_at":"2026-05-14T01:14:31+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/vertex-pharma-smashes-earnings-highlights-new-drugs","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/1ce36f17-fcde-463f-b229-eea75a80692f.mp3","audio_url":"https://api.fastcast.ai/audio/1ce36f17-fcde-463f-b229-eea75a80692f.mp3","summary":"Vertex Pharmaceuticals exceeded expectations in Q1, with $2.99 billion revenue, a 7.8% year-over-year growth, and adjusted EPS of $4.47. Management attributed success to cystic fibrosis meds and new launches like KASJEVY and Gernavix. Operating margins surged to 38.1%. Analysts questioned Vertexs competitive edge and tolerability issues, prompting insights on Povi and cystic fibrosis treatments. Future focus includes KASJEVY and Gernavix adoption, povitacicepts regulatory push, and cystic fibrosis mods expansion. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/64ef4a08e2c2af0c","meta_description":"Vertex Pharmaceuticals exceeded expectations in Q1, with $2.99 billion revenue, a 7.8% year-over-year growth, and adjusted EPS of $4.47. Management attrib…","key_points":[],"chapters":[],"topics":[],"duration_seconds":107,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/vertex-pharma-smashes-earnings-highlights-new-drugs/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/vertex-pharma-smashes-earnings-highlights-new-drugs.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}